Changing landscape of frontline therapy in chronic lymphocytic leukemia

被引：2

作者：

Bhat, Seema A. ^{[1
]}

Woyach, Jennifer A. ^{[1
]}

机构：

[1] Ohio State Univ, Comprehens Canc Ctr, 455D Wiseman Hall CCC,410 W 12th Ave, Columbus, OH 43210 USA

来源：

LEUKEMIA & LYMPHOMA | 2020年 / 61卷 / 03期

关键词：

Frontline therapy; CLL; chronic lymphocytic leukemia; BRUTONS TYROSINE KINASE; PREVIOUSLY UNTREATED PATIENTS; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; OPEN-LABEL; FCR CHEMOIMMUNOTHERAPY; INITIAL THERAPY; PHASE-III; IBRUTINIB; RITUXIMAB; VENETOCLAX;

D O I：

10.1080/10428194.2019.1688321

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The therapeutic landscape for chronic lymphocytic leukemia has significantly evolved in recent years as our understanding of the biology of this disease has advanced. Chemoimmunotherapy has been the standard frontline treatment for patients of all age groups with chronic lymphocytic leukemia over the last decade. B-cell receptor signaling pathway plays a central role in the pathogenesis of chronic lymphocytic leukemia. The advent of novel small-molecule therapy for the treatment of chronic lymphocytic leukemia targeting the B-cell receptor signaling pathway has dramatically changed the therapeutic landscape with recent studies establishing ibrutinib, a Bruton's tyrosine kinase inhibitor, as the frontline treatment of choice regardless of patient's age, performance status or risk-category. Although these current advances along with the approval of other newer agents for the treatment of chronic lymphocytic leukemia is a significant step forward, newer challenges have emerged on how to best utilize these new treatment options.

引用

页码：525 / 535

页数：11

共 68 条

[51] Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience [J].

O'Brien, Susan ;

Furman, Richard R. ;

Coutre, Steven ;

Flinn, Ian W. ;

Burger, Jan A. ;

Blum, Kristie ;

Sharman, Jeff ;

Wierda, William ;

Jones, Jeffrey ;

Zhao, Weiqiang ;

Heerema, Nyla A. ;

Johnson, Amy J. ;

Luan, Ying ;

James, Danelle F. ;

Chu, Alvina D. ;

Byrd, John C. .

BLOOD, 2018, 131 (17) :1910-1919

[52] Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial [J].

O'Brien, Susan ;

Furman, Richard R. ;

Coutre, Steven E. ;

Sharman, Jeff P. ;

Burger, Jan A. ;

Blum, Kristie A. ;

Grant, Barbara ;

Richards, Donald A. ;

Coleman, Morton ;

Wierda, William G. ;

Jones, Jeffrey A. ;

Zhao, Weiqiang ;

Heerema, Nyla A. ;

Johnson, Amy J. ;

Izumi, Raquel ;

Hamdy, Ahmed ;

Chang, Betty Y. ;

Graef, Thorsten ;

Clow, Fong ;

Buggy, Joseph J. ;

James, Danelle F. ;

Byrd, John C. .

LANCET ONCOLOGY, 2014, 15 (01) :48-58

[53] Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. [J].

Rai, KR ;

Peterson, BL ;

Appelbaum, FR ;

Kolitz, J ;

Elias, L ;

Shepherd, L ;

Hines, J ;

Threatte, GA ;

Larson, RA ;

Cheson, BD ;

Schiffer, CA .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (24) :1750-1757

[54] Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naive patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies [J].

Robak, Tadeusz ;

Burger, Jan A. ;

Tedeschi, Alessandra ;

Barr, Paul M. ;

Owen, Carolyn ;

Bairey, Osnat ;

Hillmen, Peter ;

Simpson, David ;

Grosicki, Sebastian ;

Devereux, Stephen ;

McCarthy, Helen ;

Coutre, Steven E. ;

Quach, Hang ;

Gaidano, Gianluca ;

Maslyak, Zvenyslava ;

Stevens, Don A. ;

Moreno, Carol ;

Gill, Devinder S. ;

Flinn, Ian W. ;

Gribben, John G. ;

Mokatrin, Ahmad ;

Cheng, Mei ;

Styles, Lori ;

James, Danelle F. ;

Kipps, Thomas J. ;

Ghia, Paolo .

AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (11) :1402-1410

[55]

ROGERS KA, COMMUNICATION

[56] A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRM Cancer Research Group (E1912) [J].

Shanafelt, Tait D. ;

Wang, Victoria ;

Kay, Neil E. ;

Hanson, Curtis A. ;

O'Brien, Susan M. ;

Barrientos, Jacqueline C. ;

Erba, Harry P. ;

Stone, Richard M. ;

Litzow, Mark R. ;

Tallman, Martin S. .

BLOOD, 2018, 132

[57] ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets [J].

Souers, Andrew J. ;

Leverson, Joel D. ;

Boghaert, Erwin R. ;

Ackler, Scott L. ;

Catron, Nathaniel D. ;

Chen, Jun ;

Dayton, Brian D. ;

Ding, Hong ;

Enschede, Sari H. ;

Fairbrother, Wayne J. ;

Huang, David C. S. ;

Hymowitz, Sarah G. ;

Jin, Sha ;

Khaw, Seong Lin ;

Kovar, Peter J. ;

Lam, Lloyd T. ;

Lee, Jackie ;

Maecker, Heather L. ;

Marsh, Kennan C. ;

Mason, Kylie D. ;

Mitten, Michael J. ;

Nimmer, Paul M. ;

Oleksijew, Anatol ;

Park, Chang H. ;

Park, Cheol-Min ;

Phillips, Darren C. ;

Roberts, Andrew W. ;

Sampath, Deepak ;

Seymour, John F. ;

Smith, Morey L. ;

Sullivan, Gerard M. ;

Tahir, Stephen K. ;

Tse, Chris ;

Wendt, Michael D. ;

Xiao, Yu ;

Xue, John C. ;

Zhang, Haichao ;

Humerickhouse, Rod A. ;

Rosenberg, Saul H. ;

Elmore, Steven W. .

NATURE MEDICINE, 2013, 19 (02) :202-208

[58] The B cell antigen receptor controls integrin activity through Btk and PLCγ2 [J].

Spaargaren, M ;

Beuling, EA ;

Rurup, ML ;

Meijer, HP ;

Klok, MD ;

Middendorp, S ;

Hendriks, RW ;

Pals, ST .

JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (10) :1539-1550

[59] Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study [J].

Stilgenbauer, Stephan ;

Eichhorst, Barbara ;

Schetelig, Johannes ;

Coutre, Steven ;

Seymour, John F. ;

Munir, Talha ;

Puvvada, Soham D. ;

Wendtner, Clemens-Martin ;

Roberts, Andrew W. ;

Jurczak, Wojciech ;

Mulligan, Stephen P. ;

Boettcher, Sebastian ;

Mobasher, Mehrdad ;

Zhu, Ming ;

Desai, Monali ;

Chyla, Brenda ;

Verdugo, Maria ;

Enschede, Sari Heitner ;

Cerri, Elisa ;

Humerickhouse, Rod ;

Gordon, Gary ;

Hallek, Michael ;

Wierda, William G. .

LANCET ONCOLOGY, 2016, 17 (06) :768-778

[60]

Tedeschi A, 2019, 2019 EUR HEM ASS C J

← 1 2 3 4 5 6 7 →